Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05844488 · ClinicalTrials.gov registry record
DIGITAL Biomarker: Blood Based Biomarkers in the Primary Care Setting for Alzheimer's Disease
A clinical trial, sponsored by Indiana University.
- Completed
- Registry status
- 26
- Enrollment target
NCT05844488: Completed study, sponsored by Indiana University.
NCT05844488 is a clinical trial that has completed, run by Indiana University. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05844488 has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- 26 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the feasibility of implementing blood-based biomarker testing for amyloid positivity designed to aid the early detection of Alzheimer's Disease and Related Dementia (ADRD) in patients 65+ including the rate that patients and providers follow up abnormal blood-based biomarker testing.
Primary Outcome
Evaluate the feasibility and acceptability of implementing blood-based biomarker testing for Alzhiemer's Disease and Related Dementia in primary care practices
Interventions
- DEVICE PrecivityAD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2023-03-31 |
| Est. Completion | 2023-06-30 |
What the finished NCT05844488 record still lists
NCT05844488 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 26 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which PrecivityAD is the first listed.
NCT05844488 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05844488 about?
NCT05844488 is a clinical study titled "DIGITAL Biomarker: Blood Based Biomarkers in the Primary Care Setting for Alzheimer's Disease". The primary objective of this study is to evaluate the feasibility of implementing blood-based biomarker testing for amyloid positivity designed to aid the early detection of Alzheimer's Disease and Related Dementia (ADRD) in patients 65+ including the rate that patients and providers follow up abno...
What is the current status of trial NCT05844488?
This trial is currently completed. The enrollment target is 26 participants. The study started on 2023-03-31. Estimated completion is 2023-06-30.
What interventions are being tested in trial NCT05844488?
The interventions under investigation include: PrecivityAD (DEVICE).
Who is sponsoring clinical trial NCT05844488?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI